Frigid Zone Medicine (May 2023)

Hydroxychloroquine induces long QT syndrome by blocking hERG channel

  • Zhao Xin,
  • Sun Lihua,
  • Chen Chao,
  • Xin Jieru,
  • Zhang Yan,
  • Bai Yunlong,
  • Pan Zhenwei,
  • Zhang Yong,
  • Li Baoxin,
  • Lv Yanjie,
  • Yang Baofeng

DOI
https://doi.org/10.2478/fzm-2023-0014
Journal volume & issue
Vol. 3, no. 2
pp. 105 – 113

Abstract

Read online

In March 2022, more than 600 million cases of Corona Virus Disease 2019 (COVID-19) and about 6 million deaths have been reported worldwide. Unfortunately, while effective antiviral therapy has not yet been available, chloroquine (CQ)/hydroxychloroquine (HCQ) has been considered an option for the treatment of COVID-19. While many studies have demonstrated the potential of HCQ to decrease viral load and rescue patients’ lives, controversial results have also been reported. One concern associated with HCQ in its clinical application to COVID-19 patients is the potential of causing long QT interval (LQT), an electrophysiological substrate for the induction of lethal ventricular tachyarrhythmias. Yet, the mechanisms for this cardiotoxicity of HCQ remained incompletely understood.

Keywords